NCT00918333 - Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

December 1, 2015

Study Completion Date

July 16, 2019

Conditions

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaB-cell Adult Acute Lymphoblastic LeukemiaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHepatosplenic T-cell LymphomaNodal Marginal Zone B-cell LymphomaPost-transplant Lymphoproliferative DisorderPrimary Central Nervous System Non-Hodgkin LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Multiple MyelomaSplenic Marginal Zone LymphomaT-cell Adult Acute Lymphoblastic LeukemiaWaldenström Macroglobulinemia

Interventions

DRUG

panobinostat

Given PO

DRUG

everolimus

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (3)

20892

Mark O Hatfield-Warren Grant Magnuson Clinical Center, Bethesda

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale